Lupus Erythematosus, Systemic Clinical Trial
Official title:
A Randomized Controlled Trial to Investigate a Contemplation-Based Intervention and Health Outcomes in Systemic Lupus Erythematosus Patients
The objective of this study is to test the efficacy of an innovative contemplative-based and caregiver-inclusive intervention can modify pathogenic processes in systemic lupus erythematosus (SLE) compared to a psychoeducation-based intervention. Contemplative techniques such as meditation, mindfulness and yoga may have an impact on the disease burden and may decrease psychological distress, increase self-regulation capabilities, and reduce pain. It is also well documented that social relationships moderate physical health. Incorporating patients' caregivers may strengthen their relationships and thereby improve their health and well-being. It is anticipated that the successful outcome of the mindfulness-based intervention described in this proposal will provide the basis for a new and effective contemplative-based and caregiver-inclusive therapy for SLE and other rheumatic diseases. Although we expect our mindfulness-based intervention to outperform our psychoeducation intervention, we note that the psychoeducation intervention is much closer to treatment as usual (especially insofar as many lupus patients are provided no psychosocial intervention whatever), and to that degree can reasonably be considered our best initial point of comparison. In practice, most patients would be provided medication and some basic information about living with the disease, as well as, perhaps, some additional guidance about coping with chronic stress and pain. We believe that our comparison condition goes beyond this to provide a bona fide intervention in itself.
METHODS: A randomized controlled trial of 50 SLE patients in which subjects receive either a
6-week MBI treatment (n=25) or a 6-week psychoeducation treatment (n=25).
SCREENING: At Visit 1, participants who are deemed eligible for the study will be assigned to
either a mindfulness-based intervention group or a psychoeducation intervention group.
Participants will also complete the following questionnaires, which will also be administered
throughout the intervention schedule:
1. Adverse Childhood Experience (ACE)
2. Adult Attachment Style Questionnaire (AAS; closeness subscale)
3. Brief Health Mindset Scale (BHMS)
4. Center for Epidemiological Studies Depression Scale Revised (CESD-R)
5. Inclusion of Other Self (IOS)
6. Interpersonal Reactivity Index (IRI; empathic concern and perspective-taking subscales)
7. Interpersonal Regulation Questionnaire (IRQ)
8. LupusPRO (patient only)
9. MacArthur Scales of Subjective Social Status (Community and Socioeconomic Status)
10. Caregiver Burden Questionnaire (support person only)
11. Multidimensional Scale of Perceived Social Support (MSPSS)
12. Pain Catastrophizing Scale (PCS)
13. Ruminative Responses Scale (RRS; short form)
14. Social Interaction Phobia Scale (SIPS)
15. State Trait Anxiety Inventory (STAI-T, STAI-S)
16. Ten Item Big Five Questionnaire
17. Toronto Mindfulness Scale (TMS)
18. Lupus Quality of Life
19. CAM Health Belief Questionnaire
INTERVENTIONS: All participants will complete either a 6-week mindfulness-based intervention
or a 6-week psychoeducation intervention. All sessions will be in-person in a group setting,
and accompanied by homework. For both interventions, participants will practice what they
learned on a daily basis as their homework. However, the mindfulness intervention may also
have video/audio homework to complete. Sessions 1-5 will last approximately 2 hours each. The
final (6th) session will be a retreat that will last approximately 4 hours. Questionnaire
data will be collected throughout the intervention.
ASSESSMENTS: Assessment visits 1 and 9 will be performed by rheumatologists and include:
complete history, physical examination, information about SLE drug treatment and laboratory
examination. Lupus disease activity and damage will be measured by Systemic Lupus
Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and systemic Lupus International
Collaborating Clinics/American College of Rheumatology Damage Index (SDI) respectively.
Information on socio-demographics, clinical variables (SLEDAI-2K and SDI), co-morbidities
(dyslipidemia, atherosclerosis, cerebrovascular disease, and others) are collected as part of
the and will be made available for the analysis in this study. Lupus serology (including
C3/C4, anti-ds DNA antibodies) and routine blood test (including complete blood count test
and chemistry panel) are also collected regularly during the patients' visits to the clinic
and will be made available for the analysis in this study.
fMRI Tasks: Participants will complete a series of questionnaires completed within 24 hours
after the visit via Qualtrics and a series of tasks while functional MRI data is recorded.
After the fMRI, there will be four cognitive tasks done on the computer outside of the
scanner. These include:
Continuous Associative Binding (CAB): The goal of this task is to track different aspects of
memory and decision-making, in particular the ability of individuals to form associations
between pairs of items presented at the same time. In the tasks, participants are presented
with pairs of images of objects (e.g., a pencil and a lamp) and their job is to indicate
whether the have seen that exact pair of images presented together in the present block of
trials.
Flanker: The goal of the flanker task is to measure inhibitory control and decision-making.
In each trial, participants are presented with a cluster of arrows pointing either left or
right. The task is for the participant to indicate the direction the arrow in the center of
the cluster of arrows is pointing.
Random Dot Motion (RDM): The goal of this task is to track attention and perceptual
decision-making. In each trial, participants see a circle filled with dots moving in
different directions. Most of the dots are moving in random directions, but some of the dots
are moving coherently either left or right. The task of the participant is to indicate
(either by the keyboard or touch screen) whether more coherent dots are moving to the right
or left.
Balloon Analog Risk Task (BART): The goal of this task is to track risk-taking behavior,
reinforcement learning, and decision-making. On each trial, the participant indicates whether
they would like to pump more air into the balloon, increasing the amount of points/money they
could earn if they collect before the balloon pops, or whether they want to collect what they
have earned and add it to the bank. If they pump and the balloon pops, they lose the chance
to collect that money for that balloon.
Support people will complete a series of questionnaires completed within 24 hours after the
visit via Qualtrics and the Handholding Task. The support person is the partner and will be
asked to hold hands with the patient for the partner portion of the task. The support person
will be connected to the shock device (STM100C Stimulator Module, BIOPAC Systems) for one
round of the task, and the shock level will be calibrated to their pain tolerance.
After the fMRI, there will be four cognitive tasks done on the computer outside of the
scanner. These include the same tasks for the participant (listed above).
For the scan, standard procedures for removal of all participant ferromagnetic objects (e.g.,
wristwatches) will be implemented, and the procedures of the study will be reviewed, insuring
that participants have an opportunity to ask any remaining questions. All standard fMRI
safety screening procedures will be done prior to the fMRI, and female participants will take
a urine based pregnancy test. Participants will complete the following tasks while in the
scanner:
Resting State Task: Mindfulness training has been shown to alter resting state connectivity
in areas related to emotions and stress (e.g., Taren et al., 2015). Thus, we will record
resting state data in all visits. Participants will be asked to rest in the scanner.
Following the resting state scans, participants will also complete selected questions from
the Amsterdam Resting State Questionnaire 2.0 to provide subjective descriptions of their
experience.
Hand holding Task: The handholding task is a measure the social regulation of the neural
response to threat. Each trial involves the presentation of 12 threat and 12 safety cues in
randomized order across blocks of approximately 7 minutes. Participants and partners will be
told that threat cues indicate a 17% chance of mild electric shock. These basic threat
paradigms will be repeated across 3 blocks of threat/safety cues and counterbalanced across
subjects. These blocks will include the alone condition, and the partner hand holding
condition in the Threat to Self task, and the partner hand holding condition in the Threat to
Partner task. Electric shock will be delivered via an automated computer controlled device
(STM100C Stimulator Module, BIOPAC Systems) to the ankle (4 mA, cf., Tursky & O'Connell,
1972). The shock level will be calibrated to each participant's pain tolerance.
Resting State Task (a second time)
All fMRI conditions will be followed by ratings using the Self-Assessment Manikins.
ANALYSIS: The main analysis is planned when all patients have concluded the MBI or
psychoeducational program, all data have been entered, verified and validated and the primary
database has been locked. Following data reduction and preparation, analysis of all
self-report and biological (e.g., fMRI) data will be conducted using hierarchical multilevel
modeling procedures designed to maximize sensitivity to both within- and between- subject
sources of variation across time, including baseline measurements pre- and post-
intervention. In addition to testing for specific group-level effects of intervention,
individual differences in response to treatment and/or in biological measures will be
assessed as a function of self-report data at both state and trait levels, modeled as
interaction effects in multilevel models.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
| Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
| Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
| Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
| Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
| Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
| Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
| Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
| Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
| Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
| Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
| Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
| Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
| Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
| Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|